On March 17, 2015, Actavis (NYSE:ACT) completed the acquisition of Allergan, creating a $23 billion diversified global pharmaceutical company and a leader in a new industry model - Growth Pharma. The combined company has broad commercial reach extending across approximately 100 countries and is anchored by strong and sustainable brand franchises, a leading global generics business, a premier pipeline, highly efficient operations and an experienced management team. Learn more about this exciting combination at www.Actavis.com.
We vigorously invest in research and development to discover and develop new treatments that meet the needs of specialty doctors and their patients.
Allergan's world-class research and development (R&D) program embodies our efforts to bring the best of medicine to life. Scientists and researchers work closely with medical specialists to transform novel compounds into new therapeutics that help improve quality of life.
Our commitment to R&D has been evident since the 1950's, when we began pioneering new treatments to help preserve and protect eye health. Since then, our investment in R&D has progressively increased to a level that is considered best in class for the industry, and we have followed our products into new specialty areas. Our R&D programs today are focused in eye care, neurosciences, medical aesthetics, medical dermatology, and urological diseases. Currently, we are investigating a rich arsenal of potential new treatments for chronic migraine, debilitating neurological conditions, eye disease, and overactive bladder, among other conditions. Significant progress in these areas is expected to be made over the next decade - advances in which we look forward playing a prominent role.
Since Allergan's founding, the ability to listen and to learn - from our customers, and from each other - has been a cornerstone of our success. Allergan's R&D culture reflects this, providing an open forum for scientists to share ideas, collaborate on projects, and gain access to the latest research. Access to world-class technology combined with intellectual stimulation results in a dynamic environment where scientists are excited about the work they do and committed to pushing the boundaries of what is possible.
Our R&D organization is structured into integrated teams that focus on discovery for different drug targets. This unique architecture affords many benefits. Scientists normally confined to specific tracks have the opportunity to be involved in the full life-cycle of development, from early-stage exploration to human clinical testing, for a much broader perspective. Additionally, meticulous research is streamlined with highly efficient project and information management, which can save years and millions of dollars from the overall cost of drug development.
Most of our discovery and development programs are initiated internally, which sets us apart from many other health care companies. Simultaneously, we explore new market opportunities and search for partnerships to develop superior technologies that are complementary to our own business model.
In short, at Allergan, there is only one way in which we view the purpose of science and innovation - to identify those needs in health care that are unsolved and commit to finding solutions through a meaningful R&D investment that fuels future growth. This is our unwavering commitment.